First Patent to Survive Post Grant Review
Congratulations to Paragon BioTeck Inc. Its US Patent No. 8,859,623 has survived a post grant review challenge brought by Altaire Pharmaceuticals. In only its 4th written decision, the PTAB found that Altaire did not prove that the Paragon patent claims were invalid as obvious in light of Altaire's earlier products.
Altaire Pharmaceuticals Inc. v. Paragon BioTeck Inc., PGR2015-00011